Drugs in development · updated 30 October 2026

CHT101: clinical trials and development status

Development codeNot approved in the USNo EMA authorisation

As of 30 October 2026 CHT101 is in 5 active clinical trials (recruiting or ongoing, phases I–III) for 13 diseases. The most advanced phase is I.

5Active trials

IMost advanced phase

13Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow CHT101 and get an email at every change or safety alert.

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

Disease	Most advanced phase	Active trials	Reference trial
Brain Neoplasms	I	1	NCT07496073
Cutaneous T cell lymphoma	I	1	NCT06914037
Head and neck squamous cell carcinoma	I	1	NCT06383507
Hematologic neoplasm	I	1	NCT07809139
Metastasis	I	1	NCT06383507
Nasopharyngeal Carcinoma	I	1	NCT06383507
Neoplasm	I	1	NCT07496073
Neurologic Manifestations	I	1	NCT07496073
Non-Hodgkin lymphoma	I	1	NCT06914037
Ovarian neoplasm	I	1	NCT06383507
Peripheral T-cell lymphoma	I	1	NCT06914037
Renal cell carcinoma	I	1	NCT06383507
Uterine cervix neoplasm	I	1	NCT06383507

Everything on CHT101

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

Italiano Français Deutsch